Clinical trial · Observational
Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)
Investigating Metabolic Characteristics of Musculoskeletal Sarcoma In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No participants meeting inclusion criteria were found.
Summary
Brief summary (as posted)
Investigators will determine whether MRSI using hyperpolarized \[1-13C\]pyruvate provide useful information of tumor malignancy in MRI-indeterminate cases. Metabolite maps of hyperpolarized \[1-13C\]lactate and H13CO3- produced from hyperpolarized \[1-13C\]pyruvate will be compared to the biopsy results of MRI-indeterminate patients and the 13C-maps of age-matched healthy subjects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma, Soft Tissue | Soft Tissue Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperpolarized 13CPyruvate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hyperpolarized 13CPyruvate and gadolinium
- description
- Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
- interventionNames
- Drug: Hyperpolarized 13CPyruvate
Primary outcomes (1)
- measure
- The product ratio difference of lactate to bicarbonate in tumor bearing regions from those in the normal-appearing tissue.
- timeFrame
- One day visit with injection during MRSI
- description
- How much metabolic contrast can be detected using hyperpolarized Carbon-13 pyruvate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: SARCOMA patients: \- MRI indeterminate solid enhancing lesion in the pelvis or extremity. ALL subjects: * Age 18 through 100 years. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent. * All races and ethnicities will be included; subjects must be able to read and speak the English or Spanish language. Exclusion Criteria: SARCOMA patients: -Subjects who have had radiotherapy to the indeterminate lesion. ALL subjects: * Subjects who have had chemotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Subjects may not be receiving any other investigational agents. * Any contraindication per MRI Screening form including implants contraindicated at 3T, pacemakers, implantable Cardioverter Defibrillator (ICD), claustrophobia. * Metallic foreign bodies in the field of view which may interfere with MRI acquisitions. * Since each subject is receiving a gadolinium based contrast agent intravenously, additional contraindications would include: eGFR ≤ 30 mL/min/1.73m2, sickle cell disease, or hemolytic anemia. * Uncontrolled psychiatric illness/social situations that would limit compliance with study requirements. * Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
References
Publications (0)
Data not yet available